Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Assembly Biosciences (ASMB) over the last 8 years, with Q3 2025 value amounting to 100.87%.

  • Assembly Biosciences' EBIT Margin rose 591900.0% to 100.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 116.83%, marking a year-over-year increase of 471200.0%. This contributed to the annual value of 159.26% for FY2024, which is 7432400.0% up from last year.
  • As of Q3 2025, Assembly Biosciences' EBIT Margin stood at 100.87%, which was up 591900.0% from 115.24% recorded in Q2 2025.
  • Assembly Biosciences' 5-year EBIT Margin high stood at 100.87% for Q3 2025, and its period low was 301.81% during Q3 2021.
  • Moreover, its 4-year median value for EBIT Margin was 156.75% (2024), whereas its average is 160.44%.
  • In the last 5 years, Assembly Biosciences' EBIT Margin tumbled by -2901900bps in 2021 and then skyrocketed by 799200bps in 2025.
  • Quarter analysis of 4 years shows Assembly Biosciences' EBIT Margin stood at 301.81% in 2021, then soared by 42bps to 175.22% in 2023, then grew by 11bps to 156.75% in 2024, then skyrocketed by 36bps to 100.87% in 2025.
  • Its EBIT Margin stands at 100.87% for Q3 2025, versus 115.24% for Q2 2025 and 105.54% for Q1 2025.